The Priority Review

Tag

RSV

1 story

  1. Clinical trials

    Pfizer registers Phase 3 study of RSVpreF revaccination in OLDER ADULTS

    Pfizer has registered a Phase 3, randomized, OPEN-LABEL study to EVALUATE the safety and tolerability of a second dose of RSVpreF given approximately 5 years after the initial dose. The study plans to enroll 750 participants, start on October 29, 2026, and reach primary completion on February 7, 2029.